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Abstract  28 
The biomedical research complex has been estimated to consume almost a quarter of a 29 
trillion dollars every year. Unfortunately, there is evidence that a high proportion of this sum is 30 
avoidably wasted. Last year the Lancet published a series of 5 papers showing how dividends from 31 
the investment in research might be increased from the relevance and priorities of the questions 32 
being asked, to how the research is designed, conducted, and reported. Seventeen recommendations 33 
were addressed to five main stakeholders - funders, regulators, journals, academic institutions, and 34 
researchers. This paper provides some initial observations on the possible impacts of the series. It 35 
appears to have provoked several important discussions and has appeared on the agendas of several 36 
key players. There are also examples of individual initiatives illustrating ways of reducing waste and 37 
increasing value in biomedical research. This momentum is likely to move more strongly across 38 
stakeholder groups, if more collaborative relationships evolve among key players; more important 39 
work is required to increase research value. A forthcoming meeting in Edinburgh will provide a 40 
forum within which to foster the collaboration needed.  41 
 42 
  43 
Introduction  44 
More than 30 years ago the adverse clinical consequences of biased under- reporting of 45 
research were clearly documented 1, and non-publication remains hugely problematic.2-5 Non-46 
publication is bad value for funders, who could double research output by ensuring all the studies 47 
they fund are published, and it puts patients and clinicians at a substantial disadvantage in making 48 
informed decisions about healthcare.6 Trial registration, supported by the International Committee 49 
of Medical Editors (ICMJE)7, has helped8,9 although it is clearly not a panacea.10,11 Other related 50 
initiatives, such as the Alltrials initiative (www.alltrials.net) and the Institute of Medicine’s recent 51 
report on data sharing12 are working to ensure that the results of all trials are reported and their data 52 
made available.   53 
Non-publication was one of four contributors to the estimated 85% of current research 54 
funding that Chalmers and Glasziou suggested in 2009 were being avoidably “wasted”13 across the 55 
entire biomedical research spectrum (e.g., clinical, health services, and basic science). Evidence of 56 
the degree and avoidability of waste in research production at each of their 4-stage model (see Figure 57 
1) has strengthened: imbalenced research question selection, poor study design14,15 and execution, 58 
non-publication16 and poor reporting17. In addition to 295 citations, the 2009 paper led the National 59 
Institute of Health Research (NIHR) in England to establish a working group to monitor and plan 60 
actions, with regular meetings and an annual closed conference. Their “Adding Value in Research” 61 
programme added an additional stage aiming to ensure that NIHR funded research: 1. addresses 62 
questions relevant to clinicians, patients and the public; 2. uses appropriate design and methods; 3. is 63 
delivered efficiently; 4. results in accessible full publication; and 5. produces unbiased and usable 64 
reports. They developed a quality improvement tool18 for these 5 stages to identify common themes 65 
and examples of good practice across their programmes. For example, since 2013, NIHR has 66 
required applicants for support of new primary research should reference an existing systematic 67 
review “ as well as including reference to any relevant literature published subsequent to that 68 
systematic review” or where no such systematic review exists applicants should undertake to review 69 
the relevant evidence (using a methodology that systematically identifies, critically appraises and then 70 
synthesises the available evidence) which “must also include reference to relevant on-going studies, 71 
e.g. from trial registries”.19  72 
Last year the Lancet published a series of articles (“Increasing value: reducing waste”) 73 
extending the 2009 analysis to 50 journal pages, with over 40 authors20-24  focused on the 5 NIHR 74 
stages (see Figure 1). As the commissioning editors noted “Our belief is that research funders, 75 
scientific societies, school and university teachers, professional medical associations, and scientific 76 
publishers (and their editors) can use this Series as an opportunity to examine more forensically why 77 
they are doing what they do … and whether they are getting the most value for the time and money 78 
invested in science.”.25   79 
The series, and an accompanying symposium26, provided a voluminous body of evidence of 80 
the problems in biomedical research, along with 17 recommendations (see Table 1) to help increase 81 
its value, covering funders, regulators, journals, academic institutions, and researchers. The problems 82 
include (although they are not limited to) whether planned research met the needs of end users.27-29  83 
Initial media attention included coverage by several newspapers including the leading 84 
German paper Der Spiegel30, although there has been almost no response from German researchers 85 
or organizations.31 Several research funders responded through meetings, working parties, and some 86 
changes of processes (see Funders section below). In the year since their publication the five articles 87 
have been downloaded 46,596 times from the Lancet.com and Science Direct.com websites. The 88 
five articles have already been cited 113 times (Scopus); were all in the top 5% of all articles indexed 89 
by Scopus; and their Altmetric scores (social media) all ranked above the 98th percentile (of more 90 
than 3 million articles scored) including 589 tweets (about 20% of which were by healthcare 91 
professionals).   92 
This follow-up paper offers an overview of the initial influence of the series. Prior to 93 
conducting the assessment a protocol was developed outlining the key players, the methods of our 94 
investigation, including sampling frames (see Panel 1 with more detail in Appendix 1). The primary 95 
focus was to examine what funders, regulators, journals, academic institutions, and researchers are 96 
doing, and plan to do, to address waste in biomedical research.  97 
Funders 98 
A few funders have already responded to the series. In May 2014, The French Institute of 99 
Health and Medical Research INSERM (Institut National de la Santé et de la Recherche Médicale), 100 
in conjunction with the EQ 101 
UATOR network, organised a 1-day conference in Paris on “Improving reporting to 102 
decrease the waste of research” with the head of the Wellcome Trust and NIHR’s HTA programme 103 
among the speakers (video of all sessions is available on the EQUATOR website.32 The series was 104 
included in recent discussions of INSERM’s strategic plan for 2016-2020, and was presented at the 105 
annual meeting of INSERM team leaders.33 In Australia, the National Health and Medical Research 106 
Council (NHMRC) set up a working party to review all the recommendations in the series34, 107 
updating and modifying their procedures, and also featured an opening session on “Adding Value, 108 
Reducing Waste” at their 2014 annual scientific meeting35 The series was also on the agenda of the 109 
Heads of International Research Organizations (HIRO) group’s meeting in 2014.  110 
We are also heartened that concern about poor replicability and quality of much animal and 111 
other preclinical research36 has prompted some influential organisations to draw attention to and 112 
address these concerns. For example, a meeting on ‘Reproducibility and reliability of biomedical 113 
research’ was convened jointly by the UK Academy of Medical Sciences, the UK Medical Research 114 
Council, the Wellcome Trust and the Biotechnology and Biological Sciences Research Council.  The 115 
National Centre for the Replacement, Refinement and Reduction of Animals in Research 116 
(www.nc3rs.org.uk) has supported three international meetings (in Nijmegen, Edinburgh and 117 
Washington DC) on systematic reviews of animal research, and this year held an international 118 
meeting on biased under-reporting of animal research37, bringing together several relevant groups 119 
targeted in the series. Whether or not the Lancet series had any role in these initiatives, they are very 120 
welcome.  121 
The examination of the funder’s websites (see Methods panel) indicates that most funders 122 
are not explicit about many of the key issues, making it challenging to evaluate them. The NIHR had 123 
a number of innovative and exemplary features, such as requirements for systematic reviews before 124 
embarking on additional primary studies, active monitoring of ongoing studies, and its own journal. 125 
For other funders, the picture was more mixed (see Table 2). Most required trial registration, but few 126 
required systematic reviews prior to additional primary studies, or mentioned reporting guidelines, 127 
such as CONSORT, or the EQUATOR Network. Regarding conduct of systematic reviews before 128 
additional primary research, most funding organisations only required systematic reviews before 129 
considering funding future clinical trials. NIHR was an exception in that they ask for a systematic 130 
review for any research projects being submitted to them (see Table 1; 3rd recommendation from 131 
series). Only two of these funders had a substantial targeted research scheme that addressed priority 132 
questions for clinicians and patients: the NIHR’s Health Technology Assessment program, and the 133 
Patient-Centered Outcomes Research Institute (PCORI) in the United States.  134 
To maximize research value funders may want to consider ways to enhance their funding 135 
priorities in line with existing (regional, national, and international) priority setting initiatives (See 136 
Table 1; 2nd recommendation). Similarly, funders may want to enhance efforts to ensure that 137 
wherever possible protocols are developed using relevant guidance, such as SPIRIT for randomized 138 
trials and PRISMA-P for systematic reviews (see: www.equator-network.org/), and that the research 139 
they fund is registered in a relevant repository (e.g., World Health Organization’s International 140 
Clinical Trials Registry Platform - http://www.who.int/ictrp/en/, and PROSPERO) (See Table 1; 141 
4th recommendation). For example, a review of 75 recently funded randomized trial protocols at one 142 
granting agency showed they often did not provide adequate information about allocation sequence 143 
generation (13% missing) and concealment (19% missing): important characteristics of well 144 
conducted randomized trials.38 Funders could also consider stronger policies to support (guidance, 145 
education, and infrastructure) and enforce (incentives and penalties) publication of all research, open 146 
access, and data sharing.  147 
Regulators 148 
Regulators can help here by not providing ethics approval of protocols that are scientifically 149 
inadequate. Research proposals that are scientifically poor are, by definition, ethically inadequate.  150 
For example, the guidance for researchers issued by the newly established Health Research 151 
Authority (HRA) 39 in the UK now states “Any project should build on a review of current 152 
knowledge. Replication to check the validity of previous research is justified, but unnecessary 153 
duplication is unethical.”   154 
On the other hand, research regulators can reduce waste resulting from inefficiencies in 155 
research regulation. Some of these result from hyper-regulation of low risk non-interventionist 156 
research, such as many descriptive surveys. Following a report40 from the Academy of Medical 157 
Sciences in the UK, the HRA is now addressing this problem. As a result, proportionate measures of 158 
assessing research proposals have been introduced that take account of the plausible risks associated 159 
with the research proposals being considered.  160 
Some research regulators have also taken steps to reduce the problem of biased under-161 
reporting of research (see Table 1; 14th recommendation).  In the UK, a favourable ethics opinion 162 
for proposed clinical trials will not now be granted unless the proposed trial has been registered 163 
publicly.41  Following pressure from the Alltrials campaign, the European Medicines Agency has 164 
now committed to make available all clinical study reports (see Table 1; 5th and 13th 165 
recommendations) of research leading to marketing licences for new drugs.42    166 
Journals 167 
Given that more than half of the reports of clinical trials do not set their results in the 168 
context of the totality of evidence24, journals have much work to do to improve this situation. They 169 
can achieve this by providing specific guidance on their websites about this crucial feature and 170 
providing similar guidance to peer reviewers. In response to the series, the Lancet strengthened its 171 
requirement to put research into context (see Table 1; 3rd recommendation).43 From the beginning of 172 
this year, all research papers submitted to any journal in the Lancet family must include a ‘Research 173 
in context’ panel. The editors expressed their “hope that increasing the prominence of putting 174 
research into context in the submission and publication stages will help researchers, institutions and 175 
funders make decisions earlier in the process on which research questions to address and fund.”. 176 
Other journals have made similar efforts, such as panels asking authors ‘what this paper adds’. 177 
Something more explicit, such as the research in context panel might be more helpful.   178 
Based on our interviews with journals editors (see Methods panel) the Lancet series has been 179 
an impetus for reflection and change among some editors. It has been discussed internally during in-180 
house editorial meetings, at an editorial board retreat of one journal and is on the agenda for 181 
discussions with other editorial boards. The series has also been on the agenda of the influential 182 
editorial groups, such as ICMJE, along with other ongoing initiatives, such as the Institute of 183 
Medicine’s recent report on data sharing.12 Some journals have already acted on the series. For 184 
example, PLoS Medicine commissioned an editorial on how open access can reduce waste.44 Other 185 
concurrent initiatives focused on reducing research waste, not directly attributable to the series, are 186 
also underway. For example, a large group of rehabilitation medicine editors signed up collectively to 187 
mandate the use of reporting guidelines in their journals.45 This policy is likely to introduce a strong 188 
incentive to prospective authors across this content area to use reporting guidelines. Other fields are 189 
starting to implement similar strong guidance.46  190 
The results of examining the journals websites (see Methods panel) indicates there is wide 191 
variability of information contained on journal websites and the language used across journals (see 192 
Figure 2). This is likely to confuse prospective authors, particularly those early on in their research 193 
careers and those whose first language is not English. While journals want to maintain their 194 
uniqueness, and emphasize particular issues important to them, it might be useful to consider some 195 
items, perhaps particularly those related to the recommendations in the series, as core information, 196 
and unambiguous language that could be included across all journal websites. This might help 197 
improve matters for journals, prospective authors, and readers.    198 
One immediate goal could be for every journal to explicitly support use of reporting 199 
guidelines (see Table 1; 17th recommendation). The evidence indicates that their use is associated 200 
with increases in the completeness of reporting clinical trials.48 Approximately half of the websites 201 
mentioned reporting guidelines which is a similar proportion to that reported by Hirst and Altman 202 
in 2012.49 Far fewer journal websites explicitly mentioned the EQUATOR Network and few 203 
mentioned the use of systematic reviews in the context of reporting the main results of their 204 
research (see Table 1; 3rd recommendation).  205 
Journals can also add value to their websites by explicitly asking authors to provide more 206 
information about their methods particularly the interventions used or details of participants. For 207 
example, few (11%) reports from a sample of 255 cancer trials provided sufficient information about 208 
the interventions studied50 to allow clinicians to use the results in practice.51 Across the 10 questions 209 
used to assess the websites the results did not vary substantially by journal impact factor (< 5; ≥ 5).  210 
Academic Institutions   211 
We are aware of very little explicit attention by academic institutions to the Lancet series.  212 
One exception has been in Iran, where a group of academics are running a series of workshops on 213 
the Lancet series. Two workshops on “Biomedical research: increasing value, reducing waste’ were 214 
run in February 2015 for Directors of Clinical Research Centers, research vice chancellors, and 215 
Director Generals of Research Affairs of Medical Universities of North West Universities of Iran. A 216 
final national workshop is planned for the research deputies of all 50 Medical Universities of Iran.52  217 
Based on our e-mail survey (see Methods panel) we received complete responses from only 218 
26 of the 100 invited universities. We found that most (n=20) schools have a policy to register 219 
clinical trials in a publically accessible trial registry and to make full study reports available (n=19), 220 
but such policies are rare for protocols (n=5), analytical algorithms (n=5), and raw data (n=5).  Two 221 
of the 26 universities indicated not having an institutional policy for any of these five elements (see 222 
Table 1; e.g., 12th and 14th recommendations).   223 
Only five medical schools reported having a policy to make all study protocols publically 224 
available. At Duke University, for example, “all approved study protocols are available through the 225 
School of Medicine’s electronic IRB [Institutional Review Board] pathway”, but such a repository for 226 
study protocols seems rare elsewhere. In contrast, prospective registration of clinical trials in a 227 
publically accessible trial register is enforced by almost all institutions we surveyed. Although 228 
registration appears common among ‘top’ institutions, the extent to which this policy happens 229 
across less prestigious academic institutions is unclear. Trial registration has been required by the 230 
ICMJE since 20057, and also some governmental institutions, such as FDA in the US, require 231 
registration of all clinical trials.7 Despite these policies, only about half of all published trials are 232 
currently being registered.54 At Duke University “registration at ClinicalTrials.gov is required before 233 
IRB approval, and registration record completion is required before IRB close-out”. These examples 234 
highlight the importance of regulation to help maximize best research practice.  235 
Up to half of all initiated clinical trials remain unpublished.55 The Food and Drug 236 
Administration (FDA), in the United States, requires posting of clinical trial results in 237 
ClinicalTrials.gov within one year after study completion, but this is done for less than a quarter of 238 
trials falling within FDA’s mandatory reporting rules56, possibly due to lack of enforcement. This 239 
indicates the important role of universities in further enforcing the publication of all trial results. The 240 
majority of the responding deans said they have a policy to make publically available full publications 241 
of studies performed at their institution (see Table 1; 17th recommendation). The University of 242 
Sydney is currently in the final stages of establishing an open access policy which “will make 243 
publications available whenever copyright/archiving policies allow through its external access 244 
repository, no later than 12 months after the date of publication. Where access to the full text of 245 
collected scholarly works is not permitted by the publisher, publication of metadata and a link to the 246 
published work will be made openly available”. At the University of Groningen, “full publications 247 
are typically published in its final version in the University Repository and thus largely publically 248 
available”.  249 
Policies to make raw data and analytical algorithms publically available seem much rarer, 250 
although individual universities show promising initiatives (see Table 1; 5th and 14th 251 
recommendations). The University of Sydney has a “research data registry and Electronic Lab 252 
Notebook platform, both of which enable the publication of metadata (i.e., data about data - data 253 
that describes and gives information about other data) and data sets”. It states that “Researchers 254 
should make completed research data sets openly available for re-use by other researchers, unless 255 
this is prevented by the requirements of legislation or University policy, or ethical, contractual or 256 
confidentially obligations. If open access is not possible due to legal or policy reasons, researchers 257 
should make metadata openly available”.  258 
Other universities have less explicit policies. Cambridge University, in the United Kingdom, 259 
for example, explicitly “encourages researchers to be as open as possible in discussing work with 260 
other researchers and with the public. Once results have been published, the University expects 261 
researchers to make available relevant data and materials to other researchers, on request”. At the 262 
University of Bristol, “researchers can make study protocols, raw data and analytical algorithms 263 
publically available at the institutional data repository”. Beyond the stated policies there is no data on 264 
whether and how the universities monitor the implementation of any of these policies.  265 
The slow uptake of some of the recommendations by academic instructions is unfortunate, 266 
as a considerable proportion of all biomedical research resources go to universities57. One 267 
explanation may be the fact that university policies on these issues are rarely defined on a nationwide 268 
or even global level, making it difficult to coordinate policies. This can be illustrated by the large 269 
variety in the surveyed universities’ policies to make study materials publically available. 270 
Researchers  271 
 Motivated by the principle that it is unethical, unscientific, and wasteful to embark on 272 
research without systematically reviewing evidence of what is already known, particularly when the 273 
research involves people or animals, three Scandinavian researchers58 convened and inaugurated an 274 
international Evidence-Based Research (EBR) Network at the end of 2014. The EBR Network will 275 
urge funders, regulators, researchers, academic institutions, and journals to implement the changes 276 
needed to promote evidence-based research. Initiatives such as Trial Forge59,, and the Clinical Trials 277 
Transformation Initiative60 both aiming to improve the efficiencies of trial conduct, should also help 278 
researchers maximize the efficiencies when conducting clinical trials (see Table 1; 10th 279 
recommendation).   280 
To gauge further the researcher community about the series we surveyed them (see Methods 281 
panel). Most researchers agreed that the series was important to increase research value. However, 282 
basic scientists and clinical researchers had notably different perceptions of the concept of waste in 283 
research. For example, some basic scientists disagreed with the concept and believe waste was less 284 
important in their field (e.g., “[…] to state that 85% of research funding is wasted is an insult to 285 
current research efforts”; “There is no […] waste in pure, basic science”). Some were concerned by 286 
the risk of a negative impact of the series on the societal view of the value of research, which could 287 
result in decreased funding. The reluctance of basic researchers to face waste in research in their 288 
field contrasts with the evidence of the lack of reproducibility of basic and pre-clinical research.5,62  289 
 Most researchers endorsed the series recommendations. Nevertheless, they identified some 290 
barriers to increasing research value (see Table 3). Barriers to protocol registration and data sharing 291 
included the fear of inappropriate use of data, issues related to patient confidentiality, the protection 292 
of original researchers’ efforts, and the risk of having their ideas stolen by others. Some also 293 
considered that adherence to these recommendations could decrease researchers’ autonomy and be 294 
an obstacle to scientific discovery (e.g., “In basic science, there is a great need for flexibility to 295 
modify the protocol in response to the latest finding. Too rigorous control on the planning of 296 
experiments would simply kill the last nerve in basic research”; “Research is not a car factory”).  297 
Lack of expertise and appropriate support were also important barriers to performing 298 
systematic reviews before planning additional studies. Some researchers expressed some concern 299 
about the emergence of several quality constraints adding many discrete tasks (e.g., protocol 300 
registration, adherence to reporting guidelines, data sharing etc.) that would create a cumulative and 301 
discouraging burden for researchers (e.g., “We can't overly restrain creative scientists with 302 
organizational rules without burdening their work”). In fact, although adherence to these 303 
recommendations should have a positive collective impact for patients and researchers, perhaps 304 
researchers should be rewarded for implementing them. Finally, researchers identified important 305 
structural factors involved in waste in research such as the top-down funding system with an 306 
inappropriate identification of priorities, a questionable peer-review and selection process, the ever-307 
growing “red tape” in research, and a reward system based on quantity of publications and journal 308 
impact factor rather than on quality. It is important to take into consideration these barriers and 309 
provide appropriate education, incentives, and support to improve researchers’ compliance with 310 
these guidelines and increase research value. Nevertheless several researchers in the field of basic 311 
science have taken the lack of reproducibility and waste in research very seriously and initiatives are 312 
already underway to facilitate the implementation of these guidelines.63  313 
Looking to the Future  314 
The overall response to the 2014 series might be summed up as – some gratifying actions, 315 
but much, much more to be done. From a bibliometric and social media perspective, the series has 316 
gained some traction, which is encouraging. Recognition of the problems described in the series, and 317 
dialogue about the recommendations, and possible ways to monitor progress are important first 318 
steps. However, if we are to avoid the well known problem of failing to implement research 319 
knowledge into practice64, we will need to use systematically planned knowledge translation strategies 320 
including the use of theory-based strategies65 to influence research practice, programs, and policies 321 
of the five included groups, and others. A good starting point may be to re-visit the series’ 322 
recommendations and consider ways of monitoring of increased research value (see Table 1).  323 
Across the five groups our investigation has revealed nuggets of innovation and leadership, 324 
and indications of potential change, all of which need to be harnessed and sustained. Historically, 325 
the stakeholders have venues to talk and act within their own silos, such as the ICMJE for editors 326 
and HIRO for funders. However, we are unaware of any venue in which these groups collectively 327 
engage to discuss and cross pollinate ideas, or promote better research practice. The paradox is that 328 
the problems outlined in the series are large and complex (e.g., there are likely large systemic and 329 
cultural differences between preclinical and clinical researchers, and others, such as health services 330 
and populations health researchers, in how problematic they see waste or how they think it should 331 
be reduced) and no one group is responsible for addressing them. Harnessing research value may be 332 
optimized through more collaborative efforts. One immediate venue to help begin the dialogue is 333 
the forthcoming REWARD/EQUATOR conference (http://researchwaste.net/research-334 
wasteequator-conference/), envisaged as an annual forum to monitor progress and exchange ideas 335 
on improving the entire research system. The structure of the meeting has been set up deliberately to 336 
help promote and harness collaboration between all of the sectorial groups, and others, and will 337 
specifically include a meeting of several networks interested in improvement of at least one of the 5 338 
stages.  339 
All five targeted groups have a role to play in increasing research value. Some argue that the 340 
most effective strategy for maximizing research value may be through the leadership of funders and 341 
regulators. Funders can use funding policies to support recommendations in the series and provide 342 
guidance to researchers on how to minimize waste.  For example, the National Institutes of Health 343 
offers training in ‘Responsible Conduct of Research’ 344 
(http://grants.nih.gov/training/responsibleconduct.htm), an emphasis reflected in initiatives of 345 
some professional bodies, such as the American Psychological Association 346 
(http://apa.org/research/responsible/index.aspx).  Funders can also hold back a proportion of 347 
grant funding for research that has not yet been made publically available, to bring about better 348 
value. Regulators have the authority and enforce change in keeping with the series 349 
recommendations.42 Research ethics boards, for example, could play a greater role in checking that it 350 
has been demonstrated that more research in an area is needed and helping to ensure that all 351 
relevant studies are appropriately registered (see Table 1; 14th recommendation). Funders can employ 352 
strong financial incentives, such as holding back a proportion of grant funding for research that is 353 
not published or made publically available, to bring about better value. They can also use funding 354 
policies to support the series recommendations and provide guidance to researchers on how to 355 
minimize waste. 356 
Others argue that academic institutions are ideally placed to lead the movement to enhance 357 
research value. They are training subsequent generations of researchers, some of whom migrate to 358 
other places of employment, such as journals, funders, and academic institutions For example, 359 
perhaps universities could employ a new professional - publications officer - to help researchers, 360 
their staff, and trainees.66 Publication officers could also help researchers adhere to policies of 361 
funders and journals, such as registering their studies at inception and using reporting guidelines to 362 
report their research. Other innovations could also be integrated into the role of publications 363 
officers, including helping researchers when developing research protocols.67   364 
Another strategy that might be considered is setting adherence targets for each of the series’ 365 
17 recommendations and monitoring progress towards achieving the targets. Would it be 366 
unreasonable to consider annual increases in research value, say by 10% over the next decade? For 367 
example, a 2012 survey49 of journals’ instructions to peer reviewers shows that reference to or 368 
recommendations to use reporting guidelines during peer review was rare (19 of 116 journals 369 
assessed; 16%). Positive incremental change could be observing at least a 10% improvement in 370 
guidance to peer reviewers in the 116 journals initially surveyed. More active dissemination, in 371 
keeping with the series recommendations, might involve journal organizations, such as ICMJE and 372 
the World Association of Medical Editors, promoting use of reporting guidelines by peer reviewers 373 
and authors. This might constitute part of a toolkit for groups affected by reporting research. More 374 
generally, increases in research value can cut across stakeholders and dimensions of research (see 375 
Table 1).  These issues along with a general discussion about infrastructure needed to facilitate and 376 
monitor change in research value, and ways to fund it, will be discussed during the forthcoming 377 
REWARD/EQUATOR meeting in Edinburgh (http://researchwaste.net/research-wasteequator-378 
conference/) which is planned as a series of meetings to bring together funders, editors, and 379 
research organisations together with groups working on methods to reduce research waste..    380 
Perhaps it is also time to reconsider how the entire research awards system works? It has 381 
been in place for a considerable time and the current state of biomedical research suggests a 382 
different set of metrics and currencies may be needed to increase the value of research investment 383 
(see Table 1; 12th, 15th, and 17th recommendations). During the waste launch symposium some 384 
argued that the current reward system is conservative and not open to new ideas. Alternatives could 385 
be discussed, piloted, evaluated, and, implemented if they bring better research value.68,69 The need 386 
for a paradigm shift in the research reward system is also something else that could be discussed at 387 
the forthcoming REWARD/EQUATOR meeting. 388 
Our initial observations are based, in part, on examining websites which were often difficult 389 
to navigate. Similarly, it is possible that we missed information or that some of the content has been 390 
modified since we examined it. For example, on some journal websites ‘instructions to authors’ are 391 
modified at the beginning of the calendar year. The survey response rates were also lower than we 392 
would have liked requiring more cautious interpretation.  393 
This overview is a starting point. The plan is to publish more in-depth assessments of several 394 
of the stakeholder groups examined and encourage others to do likewise. Several of the issues 395 
reported here will be part of the deliberations at the forthcoming REWARD/EQUATOR meeting. 396 
The meeting will be a central point for funders, regulators, journals, academic institutions, 397 
researchers, and others, to help increase the value of the enormous investments made in biomedical 398 
research. We are all responsible for helping to ensure that all research is planned, conducted and 399 
reported to such high standards that it is of value to all. Everyone deserves a guarantee of reliable 400 
evidence resulting from the global research endeavours. 401 
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 593 
Table 1 594 
 595 
The Lancet series recommendations and examples of groups who can take action to discuss, 596 
endorse, and implement the recommendations and monitor progress. 597 
# Recommendation Monitoring Examples of 
groups who can 
take action 
 Research priorities 
1 More research on research should be done 
to identify factors associated with 
successful replication of basic research and 
translation to application in health care, 
and how to achieve the most productive 
ratio of basic to applied research 
Periodic surveys of the distribution of 
funding for research and analyses of 
yields from basic research 
EBRN, NIH, HIRO 
2 Research funders should make information 
available about how they decide what 
research to support, and fund 
investigations of the effects of initiatives to 
engage potential users of research in 
research prioritisation 
Periodic surveys of information on 
research funders’ websites about their 
principles and methods used to decide 
what research to support 
HIRO, JLA, EBRN, 
Cochrane  
3 Research funders and regulators should 
demand that proposals for additional 
primary research are justified by 
systematic reviews showing what is 
already known, and increase funding for 
the required syntheses of existing evidence 
Audit proposals for and reports of new 
primary research 
HIRO 
4 Research funders and research regulators 
should strengthen and develop sources of 
information about research that is in 
progress, ensure that they are used by 
researchers, insist on publication of 
protocols at study inception, and 
encourage collaboration to reduce waste 
Periodic surveys of progress in 
publishing protocols and analyses to 
expose redundant research 
EBRN, HIRO 
 Research design, conduct, and analysis 
5 Make publicly available the full protocols, 
analysis plans or sequence of analytical 
choices, and raw data for all designed and 
undertaken biomedical research 
Proportion of reported studies with 
publicly available (ideally 
preregistered) protocol and analysis 
plans, and proportion with raw data 
and analytical algorithms publicly 
available within 6 months after 
publication of a study report 
HIRO, PROSPERO, 
PRISMA-P, SPIRIT, 
clinicaltrials.gov, 
ISRCTN, WHO 
platform 
6 Maximise the effect-to-bias ratio in 
research through defensible design and 
conduct standards, a well trained 
Proportion of publications without 
conflicts of interest, as attested by 
declaration statements and then 
Trial Forge, CTTI, 
HIRO, COMET, 
OMERACT, 
methodological research workforce, 
continuing professional development, and 
involvement of non-conflicted 
stakeholders 
checked by reviewers; the proportion 
of publications with involvement of 
scientists who are methodologically 
well qualified is also important, but 
difficult to document 
STaRChild Health 
7 Reward (with funding, and academic or 
other recognition) reproducibility practices 
and reproducible research, and enable an 
efficient culture for replication of research 
Proportion of research studies 
undergoing rigorous independent 
replication and reproducibility checks, 
and proportion replicated and 
reproduced 
HIRO, ICMJE, 
WAME, NIH 
 Research regulation and management 
8 People regulating research should use their 
influence to reduce other causes of waste 
and inefficiency in research 
people regulating, governing, and 
managing research should measure 
the extent to which the research they 
approve and manage complies with 
the other recommendations in this 
Series 
Trial Forge, CTTI, 
Health Research 
Authorities, 
Research Ethics 
Boards  
9 Regulators and policy makers should work 
with researchers, patients, and health 
professionals to streamline and harmonise 
the laws, regulations, guidelines, and 
processes that govern whether and how 
research can be done, and ensure that 
they are proportionate to the plausible 
risks associated with the research 
regulators, individuals who govern and 
manage research, and researchers 
should measure and report delays and 
inconsistencies that result from 
failures to streamline and harmonise 
regulations 
PCORI, SPOR, 
Patients Canada, 
JLA, Research 
Ethics Boards 
10 Researchers and research managers should 
increase the efficiency of recruitment, 
retention, data monitoring, and data 
sharing in research through the use of 
research designs known to reduce 
inefficiencies, and do additional research 
to learn how efficiency can be increased 
researchers and methodologists 
should do research to identify ways to 
improve the efficiency of biomedical 
research 
Trial Forge, CTTI 
11 Everyone, particularly individuals 
responsible for health-care systems, can 
help to improve the efficiency of clinical 
research by promoting integration of 
research in everyday clinical practice 
people responsible for management 
of health-care systems or research 
should measure the proportions of 
patients who are enrolled in research 
Government 
ministries of 
health, hospital 
CEOs, Trial Forge, 
CTTI 
 Accessibility 
12 Institutions and funders should adopt 
performance metrics that recognise full 
dissemination of research and reuse of 
original datasets by external researchers 
assessment of the proportion of 
institutional and funding-agency 
policies that explicitly reward 
dissemination of study protocols, 
reports, and participant-level data 
HIRO, Altmetric, 
U15 (Canada),  
13 Investigators, funders, sponsors, 
regulators, research ethics committees, 
and journals should systematically develop 
and adopt standards for the content of 
surveys of how many stakeholders 
adopt international standards 
Alltrials, HIRO, 
clinicaltrials.gov, 
ISRCTN, WHO 
platform 
study protocols and full study reports, and 
for data sharing practices 
14 Funders, sponsors, regulators, research 
ethics committees, journals, and legislators 
should endorse and enforce study 
registration policies, wide availability of full 
study information, and sharing of 
participant-level data for all health 
research 
assessment of the proportion of 
stakeholder policies that endorse 
dissemination activities, and the 
proportion of studies that are 
registered and reported with available 
protocols, full study reports, and 
participant-level data 
HIRO, COPE, IRBs, 
ICMJE, WAME, 
 Reporting 
15 Funders and research institutions must 
shift research regulations and rewards to 
align with better and more complete 
reporting 
when assessing research (or 
researchers), funders and research 
institutions should consider the 
accessibility of research protocols, 
study materials, study data, and their 
use by others 
HIRO, individual 
funding agencies 
16 Research funders should take 
responsibility for reporting infrastructure 
that supports good reporting and archiving 
funders and research institutions 
should regularly report expenditures 
for reporting infrastructure and 
archiving 
HIRO, individual 
funding agencies 
17 Funders, institutions, and publishers 
should improve the capability and capacity 
of authors and reviewers in high-quality 
and complete reporting 
researchers should use reporting 
guidelines, registries, archives, etc; 
and take up training opportunities 
HIRO, CSE, EASE, 
EQUATOR, ICMJE, 
WAME, COPE 
CONSORT, 
PRISMA, STaR 
Child Health 
 598 
Alltrials -  599 
Altmetrics – Alternative metrics  600 
CONSORT – Consolidated Standards of Reporting Trials 601 
COPE – Committee on Publication Ethics 602 
CSE - Council of Science Editors 603 
CTTI – Clinical Trials Transformation Initiative 604 
EASE - European Association of Medical Editors 605 
EBRN – Evidence Based Research Network  606 
HIRO – Heads of Research Organizations 607 
ICMJE – International Committee of Medical Journal Editors 608 
ISRCTN - International Standard Randomised Controlled Trial Number  609 
JLA – James Lind Alliance 610 
NIH – National Institutes of Health  611 
PRISMA – Preferred reporting items for systematic reviews and meta-analyses 612 
StarChild Health -  613 
U15 (Canada) – Leading research intensive universities in Canada 614 
WAME - World Association of Medical Editors 615 
  616 
 617 
Table 2 618 
 619 
Information available on the websites of selected funding agencies with regard to some dimensions of “reducing waste of research” framework 620 
 621 
Funders (Country) Is there engagement 
with users of research 
in  prioritizing funding 
for future research 
(R2) 
Are systematic reviews 
a key part of the 
information to inform 
future (basic or applied) 
research priorities? (R3) 
 
Does the funder 
require prior 
registration of 
research? If so, 
which types? (R4) 
 
What is the funder’s policy 
on public access to data 
from completed research? 
(R13, R14) 
 
What is the 
funder’s policy 
on public access 
to protocols for 
completed or 
ongoing 
research? (R13) 
What is the overall process to 
set a research agenda? (R2) 
National  Institute 
for Health 
Research – NIHR 
(England) 
They involve 
researchers, policy 
makers and patient’s 
representative. Active 
patient involvement is 
key in the process. 
Outline and/or full 
applications 
(depending on specific 
research programme 
and/or funding stream) 
are peer reviewed – 
this includes a Public 
and patient 
involvement (PPI) 
reviews.  This relates 
to research 
applications. In terms 
of the decisions to 
fund applications, 
Programme Boards 
have PPI members  
who will consider 
applications from a PPI 
perspective and  
Yes, for any type of 
research The funder 
provides funding for 
systematic reviews.  
For Health Technology 
Assessment (HTA) 
applications, any 
relevant and ongoing 
clinical trials have to be 
also included.  
There is a specific system 
for monitoring the 
conduct of clinical trials. 
Reviews are carried out 
internally by NETSCC 
Programmes to ensure 
research not duplicated 
within NIHR Programme 
portfolios (and to 
identify, in certain cases, 
where research may 
feed into other NIHR 
calls for research in 
commissioned 
areas/themed calls – the 
Yes – Clinical 
Trials, and some 
other studies 
NETSCC-funded 
Patient relevant 
projects must 
register through 
www.controlled-
trials.com  onto 
the ISRCTN – 
Programme 
specific advice is 
provided 
regarding 
registration (for 
research 
application, 
contracting, start-
up processes – 
this is available 
on website). 
 
NETSCC-funded 
projects which 
include 
The rules for publishing 
completed research are 
here 
http://www.nihr.ac.uk/polic
y-and-standards/publishing-
research-findings.htm 
• the principal award holder 
submits an end-of-project 
report within 14 days study 
close. This is managed 
through NIHR monitoring 
processes 
• to meet NIHR’s open 
access commitment a copy 
of the final manuscript is 
deposited with UK PubMed 
Central upon acceptance for 
publication, to be made 
freely available as soon as 
possible and in any event 
within six months of the 
journal publisher’s official 
date of final publication. 
All of protocols 
are published on 
the programme 
website.  
NIHR Evaluation, Trials and 
Studies (NETSCC ), part of NIHR 
programme, works with 
external organisations and 
individuals, including a public 
website for suggestions, to 
identify research questions 
likely to make the greatest 
difference in people’s health. 
An advisory board prioritises 
proposals along with checks 
that there is no inadvertent 
duplication. NETSCC is now 
responsible for the James Lind 
Alliance programme of Priority 
Setting Partnerships, which 
engages clinicians and patients 
in setting research priorities 
patient need. latter is perhaps not 
completely clear on the 
website) 
systematic review 
as part of their 
protocol, must 
register protocols 
on the PROSPERO 
database.   
Medical Research 
Council – MRC 
(United Kingdom) 
For setting the 
research agenda 
stakeholder 
involvement is very 
important (includes 
department of health, 
department of 
international 
development, 
devolved 
administrations) but 
they don’t get involved 
in individual funding 
decisions. In individual 
funding decisions, 
strong involvement of 
researchers and the 
private sector (pharma 
industry); very limited 
and selective 
involvement of the 
public and patients. 
Public and patients are 
only involved in 
selective projects if 
deemed appropriate. 
No, Expert opinion 
seems to be the key 
factor.  A lot of MRC 
funding goes to basic 
laboratory work. The 
latter requires clear 
rationale based on an 
analysis of previous work 
but not a systematic 
review per se The only 
proposals requiring 
systematic assessment 
of existing evidence are 
global health clinical 
trials. 
Yes for clinical 
trials. The funding 
of large scale 
clinical trials is 
done through 
NIHR Efficacy and 
Mechanism 
Evaluation (EME) 
Programme so 
their 
requirements 
which include 
clinical trial 
registration are 
followed.  
 
MRC has policies for data 
sharing although it 
emphasizes access for 
scientists, not the public. 
The research councils in UK 
have an overall open access 
policy and give universities 
budgets to publish 
completed research in an 
open access format, 
although there is flexibility. 
There is no policy 
on protocols, only 
a policy for 
completed 
research beyond 
the requirements 
of sharing 
information as 
part of registering 
clinical trials. 
There is an overall strategic 
plan to guide decisions about 
research priorities and there 
are specific goals and objectives 
for each funding panel. The 
strategy Board , the Research 
Boards and the four overview 
groups (Public Health, Global 
Health, Translation and 
Research Careers) are heavily 
involved in setting the research 
agenda and identifying 
priorities. 
National Health 
and Medical 
Research Council  - 
NHMRC (Australia) 
Researchers are 
strongly involved. The 
degree of involvement 
of other stakeholders 
is unclear.   
No, Expert opinion 
seems to be the key. No 
explicit mention of the 
need for systematic 
reviews prior to new 
primary research. 
Yes. For Clinical 
trials only  
Yes. Publication from 
NHMRC supported research 
must be deposited into an 
open access institutional 
repository within a twelve 
months of publication but 
No. We were 
unable to identify 
a policy for access 
for protocols 
beyond the 
requirement to 
There is an overall strategic 
vision and they have health 
care, preventive and 
community health and genetic 
committees to advise them 
along with clear principles: 
don’t specifically mention 
databases. 
share information 
as part of the 
registration of 
clinical trials.  
Fairness, Transparency. 
Independence, Appropriateness 
and balance, Research 
community participation, 
Confidentiality, Impartiality, 
Quality and excellence.   
National Institute 
of Health – NIH 
(USA) 
NIH Institutes receives 
data and information 
on the burden of 
disease and disability 
from patient and 
advocacy groups, 
professional societies, 
and voluntary 
organizations.  
Clinicians and basic 
and clinical scientists 
provide input on 
scientific 
opportunities. NIH 
Institutes and Centre’s 
advisory 
councils/boards made 
up of scientific expert 
and members of the 
public make 
recommendations to 
ICs. In the first stage of 
peer review, fellow 
researchers evaluate 
the scientific merit of 
grant applications. In 
the second stage, 
advisory councils made 
up of science experts 
and members of the 
public make funding 
recommendations to 
No –NIH uses a variety of 
reports and data to 
inform these decisions 
but systematic reviews is 
not a required piece of 
information for future 
research.  
Yes for Clinical 
Trials only.  
Yes –  
The NIH Grants Policy 
Statement sets the 
expectation that grantees 
make the results and 
accomplishments of their 
activities available to the 
research community and to 
the public at large, including 
sharing of publications, 
research data, unique 
research resources, as well 
as commercialization of 
federally funded inventions. 
The NIH public access policy 
requires NIH funded 
scientists to submit final 
peer-reviewed journal 
manuscripts that arise from 
NIH funds to PubMed 
Central immediately upon 
acceptance for publication 
no later than 123 months 
after the official date of 
publication.  
NIH has clear data sharing 
policies that are part of 
terms and conditions of the 
grant. 
NIH’s RePORTER database 
provides information on the 
results of NIH funded 
No. We were 
unable to identify 
a policy for access 
for protocols 
beyond the 
requirement to 
share information 
as part of the 
registration of 
clinical trials. 
The U.S. congress sets NIH and 
its institute and centers (IC) 
funding levels and directs NIH 
attention to particular areas of 
research interest or emphasis. 
The NIH Division of 
Coordination, Planning and 
Strategic Initiatives in the NIH 
Office of the Director identifies 
important areas of scientific 
opportunity, rising public health 
challenges, and gaps in 
knowledge that deserve special 
emphasis. Trans-NIH planning 
for the Common Fund involves 
broad stakeholder input from 
multiple scientific and public 
inputs. The mission of each NIH 
institute and center generally 
focus on a different disease, 
organ, or stage of life. The 
individual ICs set their own 
research priorities considering 
the following factors, IC 
mission, available funding, 
scientific needs and 
opportunities, gaps in funded 
research, burden of disease, 
and public health need, such as 
an emerging threat.  Priorities 
are partially driven by the 
research community with their 
the IC. research to the public by 
linking information on 
publications and patents 
arising from NIH funded 
projects to project abstracts 
and administrative 
information, including 
budget 
investigator initiated proposals. 
Canadian Institute 
for Health 
Research – CIHR 
(Canada) 
Strong involvement of 
researchers, moderate 
involvement of policy 
makers, selective or 
limited involvement of 
members of public and 
industry. The 
Investigator Initiated 
program uses peer 
reviewers to evaluate 
and rank which 
proposals should be 
funded. These are 
primarily 
academics/healthcare 
providers, however, 
depending on the 
expertise required to 
review the proposal 
can also include 
knowledge users (e.g., 
policy makers, industry 
representatives).  
 
The priority-driven 
research program also 
uses peer reviewers 
but each peer review 
No, Expert opinion 
seems to be the key. 
They do encourage a 
systematic review for 
clinical trials. The specific 
requirements for 
proposals can vary 
between funding 
opportunities but the 
criteria for assess 
evidence and 
justification for research 
can include 
completeness of the 
literature review and 
relevance to study 
design/research plan.   
Yes, for clinical 
trials 
Yes. The Tri-Agency Open 
Access Policy on 
Publications 1(Tri-Agency or 
Tri-Council refers to 
Canada’s three Federal 
Research Granting Councils, 
CIHR, the Natural Sciences 
and Engineering Research 
Council (NSERC) and the 
Social Sciences and 
Humanities Research 
Council (SSHRC))requires 
that any publication arising 
from agency supported 
research must be deposited 
into an institutional or 
disciplinary repository that 
makes the manuscript freely 
accessible within 12 months 
of publication, and/or 
published in a journal that 
offers immediate open 
access or that offers open 
access on its website within 
12 months. 
 
CIHR researchers are also 
required to deposit some 
No, The Tri-
Agency Open 
Access Policy on 
Publications 
provides policy 
guidance related 
to public access 
for all completed 
research. There is 
no separate 
policy on 
protocols (except 
for the 
requirements for 
clinical trials as 
specified in 
Chapter 11 of the 
TCPS-2. All fields 
outlined in the 
WHO Trial 
Registration Data 
Set (TRDS) must 
be completed in 
order for a trial to 
be considered 
fully registered. A 
registration with 
missing 
CIHR is a health research 
funding organization. CIHR does 
not commission research of any 
kind for its own use.  
CIHR has two streams of 
funding: investigator initiated 
and priority driven.  
Investigator-Initiated research 
is researcher driven in that 
researchers submit proposals 
on subjects of their choice and 
not on subjects prioritized or 
targeted by CIHR. These 
proposals are peer reviewed 
and weighted against similar 
proposals and subsequently 
funded in order of ranking 
within the available budget.  
 
Priority-Driven Health research 
is designed to respond to 
Canada’s strategic health-
related research priorities. 
Strategic priorities are 
developed by CIHR’s Governing 
and Science Council, by 
evaluating government 
priorities, emerging needs, 
                                                          
1  
committee is tailored 
to the specific strategic 
initiative competition. 
Depending on the 
scope and nature of 
the program these 
reviewers can include 
some combination of 
patients, public, 
academics, press, 
private sector 
representatives or 
health-care providers. 
With the Strategy for 
Patient-Oriented 
Research, for example, 
CIHR is gaining 
experience developing 
peer review 
committees with 
public, academic, 
patient, provider and 
private sector 
reviewers. 
specific types of data in 
appropriate public 
databases immediately 
upon publication of 
research results. 
information or 
uninformative 
fields in the TRDS 
is unacceptable0 
trends and important 
knowledge deficits in the 
Canadian health research 
landscape.  
 
More specifically, in order to 
determine how to allocate its 
strategic funding, CIHR 
develops a five-year Strategic 
Plan based on a number of 
important inputs and involving 
many stakeholders.  Inputs 
include the Government of 
Canada Science & Technology 
(S&T) Strategy, Ministerial 
priorities and key stakeholders 
including patients, industry, 
policy makers and provincial 
health ministries. In addition 
during the strategic planning 
exercise, input from the public 
is invited through various 
electronic means. The latest 
strategic plan (Health Research 
Roadmap II:  Capturing 
Innovation to Produce Better 
Health and Health Care for 
Canadians 2014-2015-2018-
2019), was recently approved 
by CIHR’s Governing Council 
and is posted on CIHR’s 
website. 
CIHR’s Institutes and their 
Scientific Directors are also 
involved, along with their 
communities, in helping to 
inform the directions of CIHR’s 
Priority-Driven programs 
through the design of initiatives 
that service the priorities of 
their research communities. 
This process often includes 
consultations with researchers, 
partners, patients, etc. 
Each CIHR institute also has 
their own strategic plan that 
aligns with CIHR’s strategic plan 
(as mentioned above) and is 
available on CIHR’s website. 
CIHR’s Governing Council is 
comprised of 18 women and 
men who are able to contribute 
to the achievement of CIHR's 
objectives in the overall 
interests of Canadians; each 
come from a unique 
background and possess an 
outstanding skill set; reflect a 
range of relevant backgrounds 
and disciplines. 
Deutsche 
Forschungsgemeins
chaft –DFG 
(Germany) 
Researchers are 
involved in reviewing 
and making decisions. 
For some proposals, it 
goes to the joint 
committee that 
involves policy makers 
too.  
n the decision making 
process, the proposal 
is evaluated by 
voluntary reviewers 
(scientists) exclusively 
according to scientific 
criteria; on the basis of 
this expert review, it is 
Yes for clinical trials The 
current state of the 
research field and 
evidence is to be 
presented in the 
proposals. For clinical 
trials, the structured 
search for evidence has 
to be described or 
systematic reviews to be 
referenced. The 
comprehensive 
description of the 
existing evidence is a key 
reviewing criterion. 
Systematic reviews can 
Yes for clinical 
trials only 
There are suggestions and 
examples for researchers on 
reusing research data. DFG 
strongly encourages 
researchers to have 
strategies to reuse data “In 
order to enhance the long-
term archiving and curation 
of research data, the DFG 
funds projects that seek to 
achieve an efficient reuse of 
research data” but it isn’t 
compulsory. 
All clinical trials 
funded after the 
1.6.2014 have to 
deposit the study 
protocol at the 
clinical trials 
registry prior to 
trial start but not 
for other study 
designs.  
The DFG is the self-governing 
organisation for science and 
research in Germany. It serves 
all branches of science and the 
humanities. The chief task of 
the DFG is to select the best 
research projects by scientists 
and academics at universities 
and research institutions on a 
competitive basis and to 
finance these projects. Projects 
are presented by scientists and 
academics or by universities in 
a proposal dealing with their 
chosen topics from a particular 
discipline or taking an 
assessed by chosen 
members of the 
Review Board 
(scientists), and the 
final decision is taken 
by the Grants 
Committee. There are 
different Grants 
Committees involved 
for the different 
programmes of DFG 
funding. They consist 
of researchers, 
representatives of the 
federal and the state 
governments as well as 
from the Donors’ 
Association for the 
Promotion of Sciences 
and the Humanities in 
Germany. Members of 
the standing review 
boards all elected by 
the scientific 
communities every 
four years. 
be funded in the 
individual grants 
programmes. 
interdisciplinary approach. In a 
multi-layered decision making 
process, the proposal is 
evaluated by voluntary 
reviewers exclusively according 
to scientific criteria; on the 
basis of this expert review, it is 
assessed by chosen members of 
the Review Board, and the final 
decision is taken by the Grants 
Committee. In this way, DFG 
funding guarantees quality-
based differentiation in the 
German research system.  
 
In keeping with the DFG’s 
concept of its role as a self-
governing organisation, any 
eligible researcher may submit 
a funding proposal at any time 
and on any research topic. As 
the DFG does not specify a topic 
for proposals, but, instead, 
reacts to proposals on any 
topic, it promotes research 
primarily in what is known as 
“response mode”, thereby 
complementing the agenda 
driven and programme oriented 
funding by the ministry of 
research and education. (BMBF) 
in Germany. 
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Table 3 623 
Barriers to reducing waste in research identified by researchers  624 
and facilitators to increasing research value 625 
 626 
# Recommendations Barriers identified Facilitators 
3 Perform a 
systematic review 
of all available 
evidence before 
planning a study 
Basic Researchers (BR):  “The primary barrier is the vast 
amount of information that has to be surveyed combined 
with reduced time to linger and concentrate on a given 
project in university institutions in general.” 
BR: “There is no such thing as all available evidence. What 
constitutes evidence for a particular study is integral part of 
the conceptualization of the study. Different people have 
legitimately different methods in using evidence. Too much 
evidence, some of which is just bad data, can be paralyzing 
and prevent innovation.” 
Clinical Researchers (CR): “Very expensive and time 
consuming to do full systematic reviews and most 
researchers aren't good at it.” 
Funders to make 
systematic review a 
condition for grant 
submission; Funders 
and journals to 
collaborate on 
developing 
educational toolkits 
for “research in 
context”; Institutions 
to provide 
methodological and 
logistical support to 
researcher to perform 
systematic reviews 
14 Systematically 
register study 
protocol at 
inception 
BR:“A registry will add extra work and a collection of 
information that will not correspond to the actual 
experiment.” 
CR: Lack of knowledge in how and when to register. 
Develop appropriate 
register for basic 
scientists; Develop 
researcher toolkits 
for use of the World 
Health 
Organization’s 
International Clinical 
Trials Registry 
Platform, 
PROSPERO, and 
other relevant 
repositories. 
5 Make the full 
protocol publicly 
available 
BR: This demand would make it impossible for smaller 
groups to come to new break throughs even though it is 
their idea 
CR: Takes time and innovative ideas might be hard to 
publish once it’s on the public domain 
To develop 
appropriate 
repository for basic 
scientists; to provide 
specific funding and 
logistical support to 
researchers to make 
these documents and 
data available; 
funders, institutions, 
5 Make the analysis 
plan publicly 
available 
BR: Obviously these questions are not for basic research 
but for applied clinical research 
CR: I would love to do this, but usually there is too little 
time to complete the analysis plan 
15 Systematically BR: Time waste, need lot of time to write negative 
make their results 
publicly available  
experiments. 
CR: Negative results are less likely to have enthusiasm for 
publication. 
editors to reward 
researchers making 
the protocol, analysis 
plan, results, raw 
data publicly 
available. 
5 Make raw data 
publicly available 
BR: Lack of suitable repositories-lack of funding to 
establish these. 
CR: This would create many problems of confidentiality 
etc. that would require redacting and involve a lot of 
"wasted" time. There is also probably reluctance to give 
access to such data because others may use them for their 
own purposes. 
CR: massively sharing data could lead to inappropriate use, 
as the context of data collection, the objective of the study, 
are necessary to understand their meaning. 
  627 
Figure 1: Stages in research production (stage 3 – dashed box – added to 2009 model by NIHR).  628 
 629 
Please see PowerPoint slide (Waste initial observations figure 1).   630 
 631 
 632 
 633 
Figure 2 634 
 635 
Frequency of responses to 10 questions from websites of 119 core clinical journals included in 636 
Medline’s Abridged Index Medicus (http://www.nlm.nih.gov/bsd/aim.html).  637 
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 643 
Q1 – Does journal ITA explicitly mention reporting guidelines (such as CONSORT)? 
Q2 – Does journal ITAs explicitly mention the EQUATOR Network? 
Q3 – Does journal ITA explicitly mention clinical trial, systematic review, or other  
         registration (such as PROSPERO; indicate which one(s) specifically)? 
Q4 – Does the journal ITA mention use of systematic reviews as part of reporting main  
         study results (e.g., item 23 of CONSORT**)? 
Q5 – Does the journal’s Instruction to Authors recommend authors to go to the ICMJE  
         Website for guidance? 
Q6 – Does the journal support publishing “research on research”, such as a “methods and  
         reporting section”? 
Q7 – Has the journal published editorials highlighting the series, other pieces on waste,  
        duplication, reporting guidelines, registration, other topics related to increasing value? 
Q8 – Does the journal provide support for good reporting infrastructure? 
         Ex: study registries, data repositories, other 
Q9 – Does the journal mention open access? 
Q10 – Does the journal have a policy on public access to data from completed research? 
 
